A Bioequivalence Study of CT-L02 Compared to Co-administration (CTL0201 and CTL0202) in Healthy Volunteers

A Randomized, Open, Single-dose, Crossover-design, Phase I Study to Evaluate the Safety and Pharmacokinetics After Co-administration of CTL0201 and CTL0202 or Administration of CT-L02 in Healthy Volunteers

This is a randomized, open, single-dose, crossover-design, phase I study to evaluate the safety and pharmacokinetics after co-administration of CTL0201 and CTL0202 or administration of CT-L02 in healthy volunteers.

Inclusion Criteria:

• Healthy participant aged 19 to 55 years, at screening
• A participant who has a body mass index (BMI) of 18.0~29.9 kg/m2, at screening
• A participant who is judged to be eligible to participate by the results of screening tests (vital signs, clinical laboratory tests, 12-lead ECG, etc.) by the principal investigator

Exclusion Criteria:

• A participant who has taken drugs that induce or inhibit drug metabolizing enzymes
• A participant who has participated in other clinical trials or bioequivalence studies within 6 months prior to the first dose of the investigational drug
• A participant who has a history of gastrointestinal surgery that may affect drug absorption